We are live on
!
Find out more
KL
KCK Ltd Portfolio holdings
AUM
$15.1M
1-Year Est. Return
30.14%
This Fund
S&P 500
This Quarter
Est. Return
+38.65%
1 Year Est. Return
+30.14%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$75M
AUM Growth
–
Cap. Flow
+$65.8M
Cap. Flow
% of AUM
87.81%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
3
New
3
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neuropace
NPCE
|
+$45.8M |
| 2 |
Sight Sciences
SGHT
|
+$19.9M |
| 3 |
RNTX
Rein Therapeutics
RNTX
|
+$67.7K |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Neuropace
NPCE
$474M
| $59M | 78.69% |
+5,270,845
| New | +$45.8M |
|
|
2
Sight Sciences
SGHT
$391M
| $15.9M | 21.25% |
+4,374,975
| New | +$19.9M |
|
|
RNTX
3
Rein Therapeutics
RNTX
$67.4M
| $51.4K | 0.07% |
+22,341
| New | +$67.7K |
|
Similar funds
LM
AVM
RCMU
TPC
SI
TAC
DADR
PM
KCK Ltd's Q4 2024 Portfolio in Review
Q4 2024 is the first quarter with a 13F filing on record for KCK Ltd, which disclosed 3 positions worth $75M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is Neuropace: 5,270,845 shares worth $59M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- KCK Ltd's largest Q4 2024 buy was Neuropace: 5,270,845 shares worth $59M.
- KCK Ltd's ten largest holdings make up 100% of its $75M portfolio in Q4 2024.
- KCK Ltd disclosed 3 positions in Q4 2024, its first 13F filing on record.
Based on KCK Ltd's 13F filing for Q4 2024, filed 15 Jan 2025.